|
Tropical Theileriosis
The Laboratory has developed
the technology for the production of an effective
vaccine against Tropical Theileriosis, a deadly
protozoan disease of exotic cattle and their crosses.
Immunisation with the vaccine has enabled the farmers to keep crossbred and exotic cows in areas
where the disease is endemic. The vaccine
is marketed under the name Rakshavac-T
by the Indian Immunologicals Limited. at Hyderabad.
FMD
The Laboratory plays a vital
role in monitoring and updating the Foot &
Mouth Disease (FMD) vaccine -
Raksha. It is a recognised centre
of the Indian Council of Agriculture Research's All India Coordinated Research Project for Epidemiological
Studies on FMD and also serves as the FMD
Virus Typing Centre for the states of Gujarat
and Madhya Pradesh.
In 1983, NDDB
established Indian Immunologicals Limited (IIL) at Hyderabad,
Asia's largest FMD Vaccine plant with an installed
annual capacity of 25 million doses of quadrivalent
vaccine. Beginning in 1986, the Biotechnology
Laboratory has implemented the FMD Virus Cataloguing
and Strain Differentiation Project. On the
basis of the project's findings, it has been possible
to incorporate the most appropriate FMD virus
strains in Raksha FMD Vaccine, ensuring it remains
effective against the Indian isolates of FMD virus.
Diarrhoea
The Laboratory has developed
a Sensitive Test for identification of
the pathogenic enterotoxigenic Escherichia
coli, a causative agent of diarrhoea in calves.
Efforts are now underway to develop a recombinant
vaccine against rotavirus, another agent involved
in calf diarrhoea.
Haemorrhagic
Septicaemia (HS)
Presently, alum precipitated
vaccine is widely used in India to prevent Haemorrhagic
Septicaemia, an acute bacterial disease caused
by two serotypes (B&E) of Pasteurella multocida.
As the duration of the immunity produced by this
broth vaccine is very short and the acceptability
of the oil adjuvant vaccine is low among the farmers,
the Laboratory is developing a Recombinant Vaccine
using gene coding for outer membrane proteins
of the organism.
Brucellosis
Technology for the commercial
scale production of diagnostic reagents has been
transferred. Facilities for confirmation of brucellosis
using polymerase chain reaction have been created.
A strain of Brucella abortus that
would be able to provide protection against field
challenge, at the same time not interfere in testing
is being developed. Genetic markers associated
with virulence of Brucella abortus strains
are being developed.
|